
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) – Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for Voyager Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.41) for the year, down from their prior forecast of ($1.32). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at $0.12 EPS.
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.02. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative return on equity of 63.42% and a negative net margin of 416.32%.
Several other analysts have also weighed in on VYGR. Wall Street Zen lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Weiss Ratings lowered Voyager Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.
View Our Latest Analysis on VYGR
Voyager Therapeutics Trading Down 5.8%
Shares of VYGR stock opened at $1.63 on Tuesday. Voyager Therapeutics has a 1 year low of $1.58 and a 1 year high of $5.48. The business’s fifty day moving average is $2.34 and its 200-day moving average is $3.34.
Hedge Funds Weigh In On Voyager Therapeutics
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Voyager Therapeutics during the 2nd quarter worth about $18,102,000. Renaissance Technologies LLC boosted its holdings in shares of Voyager Therapeutics by 95.0% in the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock worth $2,231,000 after buying an additional 281,574 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the second quarter worth about $122,000. Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics in the second quarter worth about $117,000. Finally, DLD Asset Management LP purchased a new position in shares of Voyager Therapeutics in the second quarter worth approximately $70,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
Featured Articles
- Five stocks we like better than Voyager Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
